Loading
A phase 1/2 trial of ANS02 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07538804 by Avistone Biotechnology Co., Ltd., with 294 participants planned, started 2026-07-10 and due to reach its primary completion in 2029-06-30. Interventions recorded: ANS02.
Shares Avistone Biotechnology, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Avistone Biotechnology, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.